es > en

> Biología y Técnica de la Radiación, S.L. Joins Palex Medical


The Palex group, leaders in providing advanced solutions in the area of medical supplies, laboratory products and industry materials, with more than 65 years' experience, has expanded its number of specialties and strengthened itself as a leading company in the field of technology aimed at offering precise and localized radiation therapy.

With this operation, the Palex group, which is owned by Ergon Capital (2020) and Corpfin Capital (2016), welcomes a new addition by acquiring the activity branch of Bioterra, S.L., located in Madrid.

Bioterra is a company that specializes in providing services to the Radiation Oncology, Physical and Radiation Protection departments of hospitals in Spain.

Bioterra offers highly innovative solutions for cancer treatments, which include techniques such as radiotherapy guided by magnetic resonance imaging and proton therapy; information and planning systems; dosimetry and immobilization systems for the patient.

The incorporation of the Bioterra team represents the creation of a new business unit dedicated to radiotherapy that strengthens Palex's commitment to oncology, expanding its range of products that cover everything from early detection to treatment, without forgetting about the Equashield®, a Closed System Transfer Device for compounding, which guarantees the safety of professionals when handling hazardous types of medications.

Marisa Ogando, Director of Bioterra: "The incorporation of Bioterra into the Palex group strengthens the structure that is required in order to guarantee maximum support for our users. Bioterra's experience in the Radiation Oncology sector is joined by the implementation and dedication to continuous improvement of the Palex group, to establish itself as the leading provider of the most advanced solutions.“

Xavier Carbonell, CEO of the Palex group, highlights: "We are always there for professionals, working to detect their needs and guide our solutions and services to be in line with the evolution of each field and medical specialty. Our obligation is to find solutions that satisfy these new needs and we are once again committing to innovation and service.”

Other news

> Share in